An insider automatic stock sale is a plan (often called a 10b-5 plan) that provides that an insider will trade shares automatically in amounts and on dates set forth in the plan. It could be "sell 1,000 shares every Friday" or it could be very complicated (e.g. "sell 1,000 shares if the price hits $10 and the trading volume is at least 100,000 shares"). The reason for it is because insiders often can't sell because they have insider information. Trading with inside information is illegal. But by having an automatic plan, the insider is not trading on inside information (the trade is automatic and will happen regardless of any inside knowledge).
where is the results from the testing done in Europe ? Are they part of this pier review ? What is so hard about reading results and saying great results or this is a waste ? Starting to smell I.M.O
Seeking Alpha is a bucket of bull crap I wouldn't trust anything they say . they seem to pump and dump IMO
I'm holding too and totally agree with you
Are you going to dump it or ride it out keep
Why are you here just lonesome ?
You have a lot of nerve talking to azra this way it was an opinion, just like yours . It's people like you that keep honest and wanting to learn people from posting on message boards.
Roche to Buy Drug Maker InterMune for $8.3 Billion
The Swiss drug maker Roche is buying InterMune, a specialist in treatments for breathing diseases, for $8.3 billion, as pharmaceutical firms continue to seek new products to bolster their offerings
A new treatment for macular degeneration is close to the next stage of human testing—a noteworthy event not just for the millions of patients it could help, but for its potential to become the first therapy based on embryonic stem cells.
This year, the Boston-area company Advanced Cell Technology plans to move its stem-cell treatment for two forms of vision loss into advanced human trials. The company has already reported that the treatment is safe (see “Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy”), although a full report of the results from the early, safety-focused testing has yet to be published. The planned trials will test whether it is effective. The treatment will be tested both on patients with Stargardt’s disease (an inherited form of progressive vision loss that can affect children) and on those with age-related macular degeneration, the leading cause of vision loss among people 65 and older.
The treatment is based on retinal pigment epithelium (RPE) cells that have been grown from embryonic stem cells. A surgeon injects 150 microliters of RPE cells—roughly the amount of liquid in three raindrops—under a patient’s retina, which is temporarily detached for the procedure. RPE cells support the retina’s photoreceptors, which are the cells that detect incoming light and pass the information on to the brain.
Although complete data from the trials of ACT’s treatments have yet to be published, the company has reported impressive results with one patient, who recovered vision after being deemed legally blind. Now the company plans to publish the data from two clinical trials taking place in the U.S. and the E.U. in a peer-reviewed academic journal. Each of these early-stage trials includes 12 patients affected by either macular degeneration or Stargardt’s disease.
The more advanced trials will have dozens of participants, says ACT’s head of clinical development, Eddy Anglade. If proved safe and effective, the cellular therapy could preserve the vision of millions affected by age-related macular degeneration. By 2020, as the population ages, nearly 200 million people worldwide will have the disease, estimate researchers. Currently, there are no treatments available for the most common form, dry age-related macular degeneration.
ACT’s experimental treatment has its origins in a chance discovery that Irina Klimanskaya, the company’s director of stem-cell biology, made while working with embryonic stem cells at Harvard University. These cells have the power to develop into any cell type, and in culture they often change on their own. A neuron here, a fat cell there—individual cells in a dish tend to take random walks down various developmental paths. By supplying the cultures with fresh nutrients but otherwise leaving them to their own devices for several weeks, Klimanskaya discovered that the stem cells often developed into darkly pigmented cells that grew in a cobblestone-like pattern. She suspected that they were developing into RPE cells, and molecular tests backed her up.
Now that her discovery has advanced into an experimental treatment, Klimanskaya says she is excited by the hints that it may be able to preserve, and perhaps restore, sight. She recalls a voice mail she received during her second year at ACT: a person blinded by an inherited condition thanked her for her work, whether or not there was a treatment available for him. “When you get a message like this, you feel like you are not doing it in vain,” she says.
comments. Share your thoughts »
I called two weeks ago Young was gone . Spoke with his replacement and all he could say is were moving forward be patient. I would have posted it that day but this board is not the nicest place to post.
All this crying about Obama can't wait for president Clinton to take office